Merck & Co. Inc. share price logo

Merck & Co. Inc. Share Price

NYSE: MRK

Mega Cap

$99.70

-1.19

(-1.17%)

as on

Merck & Co. Inc. Stock Performance

as on December 6, 2025 at 2:29 am IST

  • Day's Low

    Day's High

    $99.19
    $102.09
    downward going graph

    0.51%

    Downside

    2.40%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $73.31
    $105.84
    downward going graph

    26.47%

    Downside

    6.16%

    Upside

    downward going graph

Merck & Co. Inc. share price movements today

Previous Close
$100.89
Open
$101.40
Volume
10.8M
Day's Low - High
$99.19 - $102.09
52 Week Low - High
$73.31 - $105.84

Merck & Co. Inc. Historical Returns

1 Month Return
+ 15.58 %
3 Month Return
+ 18.59 %
1 Year Return
-3.27 %
3 Year Return
-10.04 %
5 Year Return
+ 19.88 %

Merck & Co. Inc. Stock Fundamentals & Key Indicators

Check Merck & Co. Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$249.1B

EPS (TTM)

8.9658

Dividend Yield

2.56%

Quarterly Earnings Growth YOY

0.87%

PE Ratio (TTM)

13.19

Industry PE ratio

18.176666666666666

PEG Ratio

1.0772

EBITDA

31.5B

Revenue (TTM)

64.2B

Profit Margin

29.63%

Return On Equity TTM

39.49%

Merck & Co. Inc. Stock Valuation

Track how Merck & Co. Inc. P/E has moved over time to understand its valuation trends.

Merck & Co. Inc. in the last 5 years

  • Overview

  • Trends

Lowest (9.76x)

September 30, 2025

Today (13.19x)

December 8, 2025

Industry (18.18x)

December 8, 2025

Highest (69.20x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: 13.19x

Merck & Co. Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Merck & Co. Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Merck & Co. Inc. image
Merck & Co. Inc.
BUY$249.1B19.88%13.1929.63%
Eli Lilly And Company image
Eli Lilly And Company
BUY$905.7B576.7%49.530.99%
Abbvie Inc image
Abbvie Inc
BUY$399.6B109.94%172.584.00%
Johnson & Johnson image
Johnson & Johnson
BUY$486.5B33.24%19.4927.26%
Novo Nordisk A/s image
Novo Nordisk A/s
BUY$212.7B39.57%13.1532.88%

Stock Returns calculator for Merck & Co. Inc. Stock including INR - Dollar returns

The Merck & Co. Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Merck & Co. Inc. investment value today

Current value as on today

₹1,02,650

Returns

₹2,650

(+2.65%)

Returns from Merck & Co. Inc. Stock

₹3,288 (-3.29%)

Dollar Returns*

₹5,939 (+5.94%)

Analyst Recommendation on Merck & Co. Inc. Stock

Based on 31 analysts

BUY

87.10%

Buy

12.90%

Hold

0.00%

Sell

Based on 31 analysts, 87.1% of analysts recommend a 'BUY' rating for Merck & Co. Inc.. Average target price of $106.62

Merck & Co. Inc. Share Price Target

Get share price movements and forecasts by analysts on Merck & Co. Inc..

What analysts predicted

6.49%UPSIDE

Target Price

$106.62

Current Price

$99.7

Analyzed by

31 Analysts

Target

$106.62

Merck & Co. Inc. target price $106.62, a slight upside of 6.49% compared to current price of $99.7. According to 31 analysts rating.

Merck & Co. Inc. Stock’s Investor Sentiment and Interest

Investment in Merck & Co. Inc. Shares on INDmoney has dropped by -12.35% over the past 30 days, indicating reduced transactional activity.

Time period: to

Change:-12.35% versus previous 30 day period

Search interest for Merck & Co. Inc. Stock has increased by 133% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:133% versus previous 30 day period

Merck & Co. Inc. Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
15,035
15,962
14,630
15,775
16,112
16,657
15,624
15,529
15,806
17,276
Gross Profit
11,011
11,698
10,718
12,235
12,367
12,577
11,796
12,110
12,249
14,152
Operating Income
-5,012
5,872
-1,713
5,760
6,128
3,984
4,348
5,937
5,552
7,556
EBITDA
-4,155
6,951
-772
6,744
7,448
5,606
5,695
7,315
6,423
8,137
Interest Expense
277
317
310
303
310
330
328
313
305
238
Depreciation
903
1,014
964
984
1,132
1,186
1,197
1,099
1,119
1,154
Income Before Tax
-5,335
5,620
-2,046
5,670
6,006
4,090
4,170
5,903
4,999
6,745
Income Tax Expense
637
870
-820
-
545
929
426
818
571
958
Net Income
-5,975
4,745
-1,226
4,762
5,455
3,157
3,743
5,079
4,427
5,785
Net Profit Margin
-39.74%
29.73%
-8.38%
30.19%
33.86%
18.95%
23.96%
32.71%
28.01%
33.49%

Merck & Co. Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
39,498
39,807
40,122
42,294
39,121
41,518
48,704
59,283
60,115
64,168
Gross Profit
24,564
25,777
27,210
28,785
27,105
27,900
35,078
41,872
43,989
48,975
Operating Income
7,547
5,499
6,797
8,931
7,926
5,548
13,199
18,282
2,954
20,221
EBITDA
12,448
10,823
11,951
13,992
11,374
10,180
17,899
21,315
6,907
25,706
Interest Expense
672
693
754
772
893
831
806
962
1,146
1,271
Depreciation
-
-
4,637
4,519
3,652
3,625
3,214
3,909
3,800
4,499
Income Before Tax
5,401
4,659
6,521
8,701
7,171
5,863
13,879
16,444
1,889
19,936
Income Tax Expense
942
718
4,103
2,508
1,565
1,340
1,521
1,918
1,512
2,803
Net Income
4,442
3,920
2,394
6,220
9,843
7,067
13,049
14,519
365
17,117
Net Profit Margin
11.25%
9.85%
5.97%
14.71%
25.16%
17.02%
26.79%
24.49%
0.61%
26.68%

Merck & Co. Inc. Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
4,750
-1,226
4,767
5,461
3,161
3,744
5,085
4,429
5,787
Operating Cash Flow
7,717
246
3,090
5,637
9,291
3,450
2,500
3,293
7,822
Investing Cash Flow
-334
53
-1,376
-1,069
-3,845
-1,444
-1,487
-770
-283
Financing Cash Flow
-4,269
-2,245
-2,814
1,216
-2,425
-3,009
-5,755
-3,556
2,638
Change in Cash
2,957
-1,760
-1,238
5,702
3,315
-1,370
-4,586
-659
10,187

Merck & Co. Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
3,941
2,418
6,193
9,777
7,082
12,358
14,526
365
17,133
Operating Cash Flow
10,376
6,447
10,922
13,440
10,253
14,109
19,095
13,006
21,468
Investing Cash Flow
-3,210
2,679
4,314
-2,629
-9,443
-16,555
-4,960
-14,083
-7,734
Financing Cash Flow
-9,044
-10,006
-13,160
-8,861
-2,832
2,593
-9,119
-4,810
-7,032
Change in Cash
-2,009
-423
1,871
1,967
-1,769
14
4,606
-5,864
6,409

Mutual Funds that own Merck & Co. Inc. Stock

Check out the Mutual Funds with significant holdings in Merck & Co. Inc..

Global Institutional Holdings in Merck & Co. Inc.

Funds
Holdings
Vanguard Group Inc
10.13%
BlackRock Inc
8.74%
State Street Corp
4.74%
Wellington Management Company LLP
3.08%
Geode Capital Management, LLC
2.36%
See all

Merck & Co. Inc. News & Key Events

  • img

    Today's Timeline - 04 December

    Thu, 09:50 PM

    -

    Merck faces patent cliff as Keytruda nears loss of exclusivity in 2028, prompting diversification efforts with new products.

    Thu, 10:35 PM

    -

    Merck Animal Health receives FDA conditional approval for EXZOLT CATTLE-CA1 for New World Screwworm treatment.

    Thu, 11:56 PM

    -

    Merck's launch activities for Keytruda SC in Germany must be halted due to ongoing patent proceedings.

  • img

    Today's Timeline - 04 December

    Fri, 00:23 AM

    -

    Pliant Therapeutics releases interim data on PLN-101095 trial with Merck's Keytruda for advanced solid tumors.

Insights on Merck & Co. Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Merck & Co. Inc. has shown strong revenue growth over the last three quarters, increasing from $15.52 billion to $17.27 billion. This represents an average increase of 5.1% per quarter.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Merck & Co. Inc. has shown strong performance in its net profit over the last two quarters. The net profit increased from $4.42 billion to $5.78 billion, resulting in an average quarterly growth rate of 23.5%. This consistent growth indicates a positive trend in the company's profitability.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, MRK stock has moved up by 15.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Johnson & Johnson has given 35.2% return, outperforming this stock by 38.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Eli Lilly And Company has given 14.0% return, outperforming this stock by 24.0%

About Merck & Co. Inc.

"Merck & Co., Inc. is an American multinational pharmaceutical company. The corporation conducts business outside of the United States and Canada under Merck Sharp & Dohme (MSD). It was founded as an American subsidiary of the German pharmaceutical company Merck & Co. in 1891. The company was given this name in honour of the Merck family. Merck acquired the Livogen trademark from Glaxo India for Rs 8 crore in 2000 - well over the market value. According to the company, Rofecoxib will be distributed in the Philippines via a co-marketing arrangement with the local pharmaceutical business Kopran. When Biochem Pharmaceutical Industries Ltd purchased Taloja in 2004, the firm spent a total of Rs 100 million, making it the most costly acquisition the company had made then. On March 27, 2002, a decision was made to rename the company from E Merck (India) Ltd to Merck Ltd, and the company was officially constituted on that day. This increased the firm's capacity for the manufacturing of Bulk Drugs by 33 tonnes in 2006, increasing the company's overall production capacity to 351 tonnes. In 2020, the pharmaceutical business will have six blockbuster medications or products with more than $1 billion in revenue. An antibody used to treat cancer is Keytruda, estimated to make $14.3 billion this year. Varivax is supposed to make $3.9 billion each, and Gardasil will make $1.4 billion each. Currently Merck & Co. Inc. has a market cap of $249.08 Billion. It has a P.E ratio of 13.19. The shares of Merck & Co. Inc. are trading at {current share price in dollars (in INR)}."
OrganisationMerck & Co. Inc.
Headquarters126 East Lincoln Avenue, Rahway, NJ, United States, 07065
IndustryHealth Technology
CEOMr. Robert M. Davis J.D.
E-voting on sharesClick here to vote

Key Management of Merck & Co. Inc.

Name

Title

Mr. Peter Dannenbaum

Vice President of Investor Relations

Ms. Caroline A. Litchfield

Executive VP & CFO

Dr. Dean Y. Li M.D., Ph.D.

Executive VP & President of Merck Research Laboratories

Mr. Richard R. DeLuca Jr.

Executive VP & President of Merck Animal Health

Mr. Dalton E. Smart III

Senior VP of Finance, Principal Accounting Officer & Global Controller

Mr. David Michael Williams

Executive VP and Chief Information & Digital Officer

Ms. Jennifer L. Zachary J.D.

Executive VP & General Counsel

Ms. Cristal N. Downing

Executive VP and Chief Communications & Public Affairs Officer

Mr. Robert M. Davis J.D.

Chairman, President & CEO

Ms. Betty D. Larson

Executive VP & Chief Human Resources Officer

FAQs

What is Merck & Co. Inc. share price today?

Merck & Co. Inc. share price today is $99.7 as on at the close of the market. Merck & Co. Inc. share today touched a day high of $102.09 and a low of $99.19.

What is the 52 week high and 52 week low for Merck & Co. Inc. share?

Merck & Co. Inc. share touched a 52 week high of $105.84 on and a 52 week low of $73.31 on . Merck & Co. Inc. stock price today i.e. is closed at $99.7,which is 5.80% down from its 52 week high and 36.00% up from its 52 week low.

What is Merck & Co. Inc.'s market capitalisation today?

Merck & Co. Inc. market capitalisation is $0.25T as on .

How to invest in Merck & Co. Inc. Stock (MRK) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Merck & Co. Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Merck & Co. Inc. Shares that will get you 0.0150 shares as per Merck & Co. Inc. share price of $99.7 per share as on December 6, 2025 at 2:29 am IST.

What is the minimum amount required to buy Merck & Co. Inc. Stock (MRK) from India?

Indian investors can start investing in Merck & Co. Inc. (MRK) shares with as little as ₹89.896 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹898.96 in Merck & Co. Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Merck & Co. Inc. share’s latest price of $99.7 as on December 6, 2025 at 2:29 am IST, you will get 0.1003 shares of Merck & Co. Inc.. Learn more about fractional shares .

What are the returns that Merck & Co. Inc. has given to Indian investors in the last 5 years?

Merck & Co. Inc. stock has given 19.88% share price returns and 21.76% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?